Narrow population and endpoint
The US prescribing information covers adults with HIV and lipodystrophy who have excess abdominal fat. It does not claim routine obesity treatment or overall weight loss. [1]
Compound evidence dossier · C-017
Tesamorelin: an authorised medicine and its off-label claims
An authorised medicine in the United States for a narrow HIV-related indication, promoted online for broader weight-loss and body-composition goals.
What does the evidence say?
Tesamorelin is authorised in the United States to reduce excess abdominal fat in adults with HIV and lipodystrophy; that authorisation does not establish general weight-loss, anti-ageing or performance use. Its US label says it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. No UK-authorised tesamorelin medicine was identified in the MHRA database check.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
It is an approved weight-loss medicineIncorrect
The US indication concerns reduction of excess abdominal fat in adults with HIV and lipodystrophy. The prescribing information says it is not indicated for weight-loss management because it is weight neutral.
Approval proves broad metabolic benefitOverreach
Regulatory authorisation applies to the specified population, endpoint, formulation and conditions of use. It does not validate wellness, physique or longevity claims outside that boundary.
Research-labelled tesamorelin is equivalentNot established
A matching name cannot establish equivalence to an authorised medicine. Identity, formulation, strength, sterility, stability, manufacturing controls and pharmacovigilance all matter.
It is safe because it is authorised somewhereMisleading
The US label contains contraindications and warnings, including active malignancy, pregnancy, elevated IGF-1, glucose intolerance or diabetes, hypersensitivity and fluid retention. Long-term cardiovascular safety remains unresolved. [1]
Human evidence
What have studies in people shown?
The strongest human evidence concerns one defined medicine, one indicated population and a visceral-adipose-tissue endpoint. That package cannot be pasted onto a different product or a general weight-loss claim.
Visceral fat is not the same as weight loss
A change in visceral adipose tissue can occur without a useful fall in body weight. The label describes tesamorelin as weight neutral.
Long-term clinical outcomes
The label states that long-term cardiovascular safety has not been established. A body-composition endpoint does not answer whether later cardiovascular outcomes improve or worsen.
Critical distinction
What the authorisation actually covers
Authorisation is a bounded decision. The product, indication, population, labelling and manufacturing system form one package.
- Jurisdiction
- United States. An FDA authorisation does not create a UK marketing authorisation.
- Population
- Adults with HIV and lipodystrophy who have excess abdominal fat.
- Claim
- Reduction of excess abdominal fat. The label does not authorise general weight-loss management.
- Product match
- A vial sold under the same generic name is not shown to be the authorised product without a traceable regulated supply chain.
Risk register
What could go wrong?
The authorised label provides useful risk information, but it applies to the regulated product and should not be treated as a complete safety file for an unverified vial.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Labelled warnings | Elevated IGF-1, glucose intolerance or diabetes, fluid retention, injection-site reactions and hypersensitivity require attention. |
| Contraindications | The US label includes active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and hypersensitivity to tesamorelin or excipients. |
| Long-term uncertainty | Cardiovascular safety has not been established. The value and harm of long-term off-label use cannot be inferred from a short body-composition endpoint. |
| Unverified product | A research-labelled or non-authorised vial adds identity, strength, sterility, stability and supply-chain uncertainties. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No tesamorelin product with a UK marketing authorisation was identified in the MHRA public database check. |
| United States | EGRIFTA WR is authorised for reduction of excess abdominal fat in adults with HIV and lipodystrophy. It is not indicated for weight-loss management. |
| Sport | Tesamorelin is a growth-hormone-releasing factor prohibited at all times under the 2026 WADA list. A prescription does not remove the need for a valid therapeutic-use exemption where rules require one. |
Method note
How was this judgement made?
We treated the current US prescribing information as the controlling source for the authorised claim, then checked the UK medicines database and current WADA list separately. Seller language was not used to widen the indication.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- US FDA, EGRIFTA WR prescribing information, 2025Current authorised indication, limitations, contraindications and warnings. Checked 8 August 2026.
- US FDA, EGRIFTA summary reviewRegulatory review of phase 3 trials and the authorised visceral-fat endpoint. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
Is tesamorelin approved for weight loss?
No. The US label says tesamorelin is not indicated for weight-loss management. Its authorised claim is reduction of excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin authorised in the UK?
No UK marketing authorisation was identified in the MHRA public products database check. The US authorisation does not apply automatically in the UK.
Does approval prove an online vial is equivalent?
No. Equivalence requires more than a shared ingredient name. Formulation, strength, identity, sterility, stability, manufacturing controls and lawful supply all need to match the regulated product context.
What are the main labelled risks?
The US label addresses malignancy, raised IGF-1, glucose intolerance or diabetes, fluid retention, hypersensitivity and injection-site reactions. Pregnancy and certain hypothalamic-pituitary conditions are among the contraindications.
Is tesamorelin prohibited in sport?
Yes. Tesamorelin falls within growth-hormone-releasing factors prohibited at all times by WADA. Athletes using a prescribed medicine must still follow therapeutic-use-exemption rules.
What conclusion can be carried beyond the authorised use?
Very little without new evidence. The authorisation supports a defined claim for a defined medicine and population. Broader metabolic, physique or longevity claims require their own controlled human outcome studies.
Editorial experience
From our work: how we checked this page
For topical-map item C-017, Tesamorelin: an authorised medicine and its off-label claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.